Target
$424.96 → $420.05
Current stock research snapshot · 7/8/26 49 days old
UTHRUnited Therapeutics
Investment conviction●●○○○2 of 5 · current snapshot
Research target$420.05Current stock price target
Investment thesis statusINTACTLast reviewed 7/8/26
Market cap$23.53BSnapshot value · 7/8/26
Research history
See all UTHR changes ↗What changed
Xenotransplantation + manufactured organs. Only public organ-supply play. If organ manufacturing works, demand for the entire toll-road stack compounds.
Xenotransplantation clinical progress; manufactured organ pipeline; organ shortage crisis (~100k+ US waiting list); regulatory pathway advancement.
Thesis weakens if Orenitram/Tyvaso franchise faces pricing pressure or competition, or the ~$606.7M CEO 10b5-1 selling (1.11M shares, ~$546 avg) signals negative insider conviction. (vault 2026-08)
Neutral — CEO Martine Rothblatt sold $606.7M YTD (1.11M shares) via daily 10b5-1 plan since Mar 2025 at ~$546 avg; net position flat via option exercises. [X search Aug 2026]
Snapshot · 7/8/26🟡 Mixed · ins-$9.4M · 13F 13+/11-×0.5 · short↓0.2
Snapshot · 7/8/26Timestamped research update
Deep research update
449 words · Updated Jul 25, 2026 · 4 sources
Research in development: this latest 449-word update is published for context while it is expanded toward the 1,000-word editorial standard.
United Therapeutics is a commercial pulmonary-hypertension company that also runs a long-duration organ-manufacturing and xenotransplantation program. Its xeno platform includes gene-edited pig kidney/heart xenografts plus decellularized/recellularized and 3D-printed lung scaffolds.
FY2025 revenue was $3.183B (+10.6% YoY), gross margin 87.9%, operating margin 46.9%, and net margin 41.9%. Q1 2026 revenue was $781.5M (-1.6% YoY), gross margin 82.9%, operating margin 41.7%, and net income $274.9M. Balance sheet at 2026-03-31 showed cash and cash equivalents $1.280B, marketable investments $2.191B, current assets $2.872B, current liabilities $599.1M, and PP&E $1.841B.
The investable bottleneck is the transition from bespoke organ-engineering prototypes to repeatable, human-tolerable transplantable tissue. UTHR’s moat is not only the gene-editing idea; it is the manufacturing stack required to decellularize, seed, mature, and validate complex organs at scale.
- The 2025 10-K says UHeart and UThymoKidney are development-stage xenografts from gene-edited pigs. UHeart and UKidney are built from a pig with ten gene edits; six human genes were added to facilitate immune acceptance and four pig genes were inactivated to reduce rejection / abnormal growth.
- The 2025 10-K says the Research Triangle Park regenerative medicine lab produced 830 decellularized lung scaffolds, 345 recellularized lungs, and 1.65 trillion human cells in 2025. That is a 41.6% recellularization conversion rate (345 / 830).
- The same filing says the ULung scaffold design uses 44 trillion voxels, 4,000 kilometers of pulmonary capillaries, and 200 million alveoli — a useful proxy for engineering complexity rather than a commercial manufacturing line.
- The company’s commercial cash engine still comes from Tyvaso DPI / Nebulized Tyvaso: combined sales were $1.878B in 2025, or 59% of total revenue. The xeno platform is strategically important but not yet the monetization engine.
- The 2026-07-23 8-K added transplant expert Dr. Dzau to the board; management explicitly framed his addition around the mission to address the severe shortage of transplantable organs.
The moat is the integrated manufacturing and bioengineering workflow: donor-pig gene edits, decellularization, recellularization, scaffold design, and immune-conditioning biology. The hard friction is whether the company can raise organ-yield conversion and durability enough to move from lab-scale outputs to clinically durable transplants.
- Human transplant durability / rejection control may fail even if preclinical tissue engineering improves.
- Manufacturing yield could stall below a commercially useful level; 41.6% scaffold-to-recellularized conversion is not yet obviously a scalable transplant line.
- What are the current human transplant / durability readouts for UHeart and UThymoKidney, and what endpoint would count as clinical de-risking?
- How much capex and clean-room / biomanufacturing scale-up is required to move recellularization yields and organ maturity materially higher?
INTACT
Primary and supporting material
Sources
4 sources preserved from the latest qualified research update.